# What These Hormones Do Without a Pancreas

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/what-these-hormones-do-without-a-pancreas

> To isolate what the gut hormones do outside the pancreas, researchers studied twelve people who no longer have one, and blocked the receptors. The one clear result was about bone.

## Key points

- These were receptor BLOCKERS. GLP-1 medicines are activators. Do not read across.
- Blocking GIP largely abolished the meal-driven suppression of bone breakdown (84% vs 64% of baseline).
- Blocking GLP-1 alone did not.
- In twelve people over 270 minutes, no effect on glucose, gastric emptying, appetite or food intake.
- Raises a real question about what a GIP AGONIST does to bone over years. Unanswered.

To find out what the gut hormones do *outside* the pancreas, researchers studied people who no longer have one. Twelve adults whose pancreas had been entirely removed were given drugs that **block** the GIP and GLP-1 receptors. The one thing that clearly changed was bone.[1]

> **Read the direction before anything else.** This study used receptor *antagonists*, drugs that switch these hormones off. Semaglutide and tirzepatide are *agonists*, which switch them on. Nothing here describes what a GLP-1 medicine does. It describes what the body’s own hormones were doing before anyone interfered.

## Why remove the pancreas from the question

GIP and GLP-1 are called incretins because their best-known job is telling the pancreas to release insulin after a meal. But they have receptors in many other tissues, and separating those effects from the pancreatic ones is difficult in an intact person: block the hormone, insulin changes, blood sugar changes, and everything downstream of blood sugar changes with it.

People who have had a total pancreatectomy (usually for cancer or severe chronic pancreatitis) provide an unusual natural experiment. With no pancreas, there is no insulin or glucagon response to confound anything. Whatever still happens when you block a receptor has to be happening somewhere else.

Each participant did four separate 270-minute meal tests in randomized order, receiving a GIP blocker, a GLP-1 blocker, both together, or saline, without knowing which.

## The bone result

Eating suppresses bone breakdown. It is a normal, well-described daily rhythm: after a meal, the markers of bone being dismantled fall, then recover. In this study the marker fell to **64%** of its starting value on placebo, but only to 84% and 85% when GIP was blocked, alone or together with GLP-1.

*Bone resorption marker at its lowest point after a meal, as a percentage of baseline. Lower means more suppression.[1]*

| Condition | Nadir (mean ± SD) |
| --- | --- |
| Placebo | **64% ± 15%** |
| GIP blocked | 84% ± 9% |
| GIP and GLP-1 both blocked | 85% ± 8% |

Blocking GLP-1 alone did not do this. So the meal-driven suppression of bone breakdown is substantially a **GIP** effect, and it works without any pancreatic involvement at all. That is a new piece of physiology, and no other study design could have established it.

> Your own GIP is part of why eating protects your skeleton, and it does that job without asking the pancreas.

## What did not change, and how to read that

Blocking either hormone had no measurable effect on glucose metabolism, gastric emptying, appetite, food intake, triglycerides or blood pressure and heart rate. The authors read this as evidence that those effects *require* the pancreas. With the pancreas gone, blocking the hormone changes nothing, because the pathway ran through the missing organ.

> **That reading is reasonable, but it is not the only one.** Twelve people over 270 minutes is a small, brief experiment, and small brief experiments produce null results whether or not an effect exists. The authors add a further caution of their own: the surgical reconstruction of the gut in these patients may have altered how sensitive the remaining targets are. Together, the two cautions mean these nulls are softer than they look.

One incidental finding shows the blockers were working: when the GLP-1 receptor was blocked, circulating GLP-1 levels went *up*. That is the expected signature of a feedback loop being interrupted, and it is the sort of internal check that makes the rest of the results more credible.

## What it means for someone taking one of these drugs

Directly, almost nothing, for the reason given in the warning above. The drugs activate these receptors; this study switched them off. You cannot read across.

Indirectly, it sharpens a question that does matter. Bone health during rapid weight loss is a real concern, and the fact that GIP has a direct, pancreas-independent role in the daily rhythm of bone turnover is a reason to look closely at what a GIP *agonist* does to bone over years. Tirzepatide is a GIP agonist. Nobody has that answer yet, and this study is one of the reasons the question is worth asking properly.

For what is known about body composition changes on these drugs, see [lean mass on a drug versus dieting](https://glpwatchdog.org/research/lean-mass-drug-versus-dieting).

## Frequently asked questions

### Does this study show GLP-1 drugs are bad for bones?

No, and it cannot. The study blocked these hormone receptors; GLP-1 medicines activate them. It describes what the body's own GIP does, not what a drug does.

### What did it find?

Eating normally suppresses bone breakdown, and blocking GIP largely prevented that. The marker fell to 64% of baseline on placebo but only to 84% when GIP was blocked. Blocking GLP-1 alone did not have this effect.

### Why study people without a pancreas?

To separate what these hormones do through the pancreas from what they do elsewhere. With no pancreas there is no insulin or glucagon response to confound the result, so anything that still happens must be happening in other tissues.

### Nothing else changed. Does that mean these hormones do nothing else?

Not established. Twelve people over 270 minutes is a small, brief experiment that would miss ordinary-sized effects, and the authors note that surgical reconstruction may have reduced how sensitive the remaining targets are.

### Does it matter that tirzepatide acts on GIP?

It makes the long-term bone question worth asking carefully, since GIP turns out to have a direct role in the daily rhythm of bone turnover. It does not answer it; that would need a trial measuring bone on the drug over years.

## References

1. Krogh LSL, Helsted MM, Englund A, et al. Acute effects of GIP and GLP-1 receptor antagonism in totally pancreatectomized individuals: A randomized double-blind, placebo-controlled crossover study. Diabetes, Obesity and Metabolism. 2026. PMID: 41069310. https://pubmed.ncbi.nlm.nih.gov/41069310/

---

Cite as: GLP Watchdog, Nora Bissett, "What These Hormones Do Without a Pancreas", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/what-these-hormones-do-without-a-pancreas

Canonical HTML page: https://glpwatchdog.org/research/what-these-hormones-do-without-a-pancreas

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
